ATAI Life Sciences NV- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 ATAI Life Sciences NV 公司

Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

ATAI Life Sciences NV簡介



公司代碼ATAI

公司名稱ATAI Life Sciences NV

上市日期Jun 18, 2021

CEORao (Srinivas G)

員工數量54

證券類型Ordinary Share

年結日Jun 18

公司地址Prof. J.H.Bavincklaan 7

城市AMSTELVEEN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Netherlands

郵編1183 AT

電話31207932536

網址https://www.atai.com/

公司代碼ATAI

上市日期Jun 18, 2021

CEORao (Srinivas G)

ATAI Life Sciences NV公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Christian Angermayer

Chairman of the Supervisory Board

559.23K

--

Dr. Glenn Frank Short, Ph.D.

Chief Scientific Officer

42.33K

+45.68%

Ms. Andrea Heslin Smiley

Independent Supervisory Director

4.67K

--

Ms. Sabrina Martucci Johnson

Independent Supervisory Director

--

Dr. Amir Kalali

Independent Supervisory Director

--

Dr. Srinivas Rao, M.D., Ph.D.

Chief Executive Officer, Co-Founder, Interim Managing Director

--

Ms. Anne Johnson

Chief Financial Officer

--

Dr. Gerd G. Kochendoerfer

Chief Operating Officer

--

Dr. Kevin James Craig, M.D.

Chief Medical Officer

--

Dr. Scott N. Braunstein, M.D.

Independent Supervisory Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Christian Angermayer

Chairman of the Supervisory Board

559.23K

--

Dr. Glenn Frank Short, Ph.D.

Chief Scientific Officer

42.33K

+45.68%

Ms. Andrea Heslin Smiley

Independent Supervisory Director

4.67K

--

Ms. Sabrina Martucci Johnson

Independent Supervisory Director

--

Dr. Amir Kalali

Independent Supervisory Director

--

Dr. Srinivas Rao, M.D., Ph.D.

Chief Executive Officer, Co-Founder, Interim Managing Director

--

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 5月14日週四

持股股東

股東類型

持股股東

佔比

Apeiron Investment Group Ltd

15.00%

Vanguard Capital Management, LLC

3.19%

Feilding-Mellen (Cosmo)

2.08%

Adage Capital Management, L.P.

1.92%

UBS Financial Services, Inc.

1.58%

其他

76.23%

持股股東

佔比

Apeiron Investment Group Ltd

15.00%

Vanguard Capital Management, LLC

3.19%

Feilding-Mellen (Cosmo)

2.08%

Adage Capital Management, L.P.

1.92%

UBS Financial Services, Inc.

1.58%

其他

76.23%

股東類型

持股股東

佔比

Family Office

15.07%

Investment Advisor

9.87%

Hedge Fund

6.24%

Investment Advisor/Hedge Fund

4.50%

Individual Investor

3.80%

Research Firm

1.23%

Private Equity

0.76%

Bank and Trust

0.55%

Endowment Fund

0.20%

其他

57.78%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

296

73.07M

19.93%

+23.43M

2025Q4

218

45.07M

10.88%

+16.45K

2025Q3

249

45.57M

19.55%

+12.66M

2025Q2

225

29.96M

14.58%

+6.94M

2025Q1

223

23.03M

12.83%

-2.41M

2024Q4

236

15.60M

13.86%

+2.09M

2024Q3

236

13.53M

16.71%

-545.79K

2024Q2

246

14.10M

16.43%

-259.20K

2024Q1

244

14.41M

17.26%

-14.24M

2023Q4

251

15.93M

17.75%

-1.57M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Apeiron Investment Group Ltd

55.21M

15.14%

+14.20K

+0.03%

Oct 20, 2025

Feilding-Mellen (Cosmo)

7.66M

2.1%

-39.59K

-0.51%

Jan 02, 2026

Adage Capital Management, L.P.

7.08M

1.94%

+1.65M

+30.27%

Dec 31, 2025

Brand (Florian Olaf)

5.04M

1.38%

-250.00K

-4.73%

Sep 15, 2025

Deep Track Capital LP

4.68M

1.28%

+4.68M

--

Dec 31, 2025

Candriam Luxembourg S.A.

3.09M

0.85%

--

Feb 28, 2026

Morgan Stanley Investment Management Inc. (US)

2.87M

0.79%

-360.10K

-11.13%

Dec 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

AdvisorShares Psychedelics ETF

17.55%

ARK Genomic Revolution ETF

1.6%

Invesco NASDAQ Future Gen 200 ETF

0.69%

Even Herd Long Short ETF

0.14%

Avantis US Small Cap Equity ETF

0.08%

First Trust IPOX Europe Equity Opportunities ETF

0.06%

SPDR S&P International Small Cap ETF

0.05%

Fidelity Nasdaq Composite Index ETF

0%

ProShares Ultra Nasdaq Biotechnology

0%

Avantis US Equity ETF

0%

AdvisorShares Psychedelics ETF

佔比17.55%

ARK Genomic Revolution ETF

佔比1.6%

Invesco NASDAQ Future Gen 200 ETF

佔比0.69%

Even Herd Long Short ETF

佔比0.14%

Avantis US Small Cap Equity ETF

佔比0.08%

First Trust IPOX Europe Equity Opportunities ETF

佔比0.06%

SPDR S&P International Small Cap ETF

佔比0.05%

Fidelity Nasdaq Composite Index ETF

佔比0%

ProShares Ultra Nasdaq Biotechnology

佔比0%

Avantis US Equity ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據